Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression

Neuropharmacology

Volumn 55, Issue 8, 2008, Pages 1355-1363

  Ago, Yukio ^a   Arikawa, Shinsuke ^a   Yata, Miyuki ^a   Yano, Koji ^a   Abe, Michikazu ^b   Takuma, Kazuhiro ^a   Matsuda, Toshio ^a,c  

^a OSAKA UNIVERSITY   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antidepressant; Corticosterone; Dopamine; Glucocorticoid receptor antagonist; Isolation rearing; Prefrontal cortex

Indexed keywords

CORTICOSTERONE; DEXAMETHASONE; DOPAMINE; GLUCOCORTICOID RECEPTOR ANTAGONIST; POTASSIUM ION; RU 43044; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG MECHANISM; FORCED SWIMMING TEST; IMMOBILIZATION STRESS; LOCOMOTION; MALE; MICRODIALYSIS; MOUSE; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SEROTONIN RELEASE; SOCIAL ISOLATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HINDLIMB SUSPENSION; HYDROXYCORTICOSTEROIDS; IMMOBILITY RESPONSE, TONIC; MALE; MICE; MICRODIALYSIS; MOTOR ACTIVITY; PREFRONTAL CORTEX; RECEPTORS, GLUCOCORTICOID; ROTAROD PERFORMANCE TEST; SWIMMING; TIME FACTORS;

EID: 56249089978     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.08.026     Document Type: Article

References (73)

1. 1A receptor-mediated dopamine release in vivo in the frontal cortex of mice. J. Neurochem. 83 (2002) 353-359
2. 1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex. Neuropharmacology 45 (2003) 1050-1056
3. Ago Y., Harasawa T., Itoh S., Nakamura S., Baba A., and Matsuda T. Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice. Eur. J. Pharmacol. 520 (2005) 86-90
4. Ago Y., Nakamura S., Baba A., and Matsuda T. Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex. Neuropsychopharmacology 30 (2005) 43-51
5. 1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology 51 (2006) 914-922
6. Ago Y., Nakamura S., Kajita N., Uda M., Hashimoto H., Baba A., and Matsuda T. Ritanserin reverses repeated methamphetamine-induced behavioral and neurochemical sensitization in mice. Synapse 61 (2007) 757-763
7. Ago Y., Takahashi K., Nakamura S., Hashimoto H., Baba A., and Matsuda T. Anxiety-like and exploratory behaviors of isolation-reared mice. J. Pharmacol. Sci. 104 (2007) 153-158
8. Ago, Y., Arikawa, S., Yata, M., Yano, K., Abe, M., Takuma, K., Matsuda, T. Role of prefrontal dopaminergic neurotransmission in glucocorticoid receptor-mediated modulation of methamphetamine-induced hyperactivity. Synapse, in press.
9. Aisa B., Tordera R., Lasheras B., Del Río J., and Ramírez M.J. Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats. Psychoneuroendocrinology 32 (2007) 256-266
10. Bachmann C.G., Bilang-Bleuel A., De Carli S., Linthorst A.C.S., and Reul J.M.H.M. The selective glucocorticoid receptor antagonist ORG 34116 decreases immobility time in the forced swim test and affects cAMP-responsive element-binding protein phosphorylation in rat brain. Neuroendocrinology 81 (2005) 129-136
11. Belanoff J.K., Flores B.H., Kalezhan M., Sund B., and Schatzberg A.F. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21 (2001) 516-521
12. Brenes J.C., Rodríguez O., and Fornazuera J. Differential effect of environment enrichment and social isolation on depressive-like behavior, spontaneous activity and serotonin and norepinephrine concentration in prefrontal cortex and ventral striatum. Pharmacol. Biochem. Behav. 89 (2008) 85-93
13. Cador M., Dulluc J., and Mormede P. Modulation of the locomotor response to amphetamine by corticosterone. Neuroscience 56 (1993) 981-988
14. Castren E., Voikar V., and Rantamaki T. Role of neurotrophic factors in depression. Curr. Opin. Pharmacol. 7 (2007) 18-21
15. Conti A.C., Cryan J.F., Dalvi A., Lucki I., and Blendy J.A. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J. Neurosci. 22 (2002) 3262-3268
16. Conti A.C., Kuo Y.C., Valentino R.J., and Blendy J.A. Inducible cAMP early repressor regulates corticosterone suppression after tricyclic antidepressant treatment. J. Neurosci. 24 (2004) 1967-1975
17. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23 (2002) 238-245
18. Cuadra G., Zurita A., Gioino G., and Molina V. Influence of different antidepressant drugs on the effect of chronic variable stress on restraint-induced dopamine release in frontal cortex. Neuropsychopharmacology 25 (2001) 384-394
19. Dazzi L., Serra M., Spinga F., Pisu M.G., Jentshe J.D., and Biggio G. Prevention of the stress-induced increase in frontal cortical dopamine efflux of freely moving rats by long-term treatment with antidepressant drugs. Eur. Neuropsychopharmacol. 11 (2001) 343-349
20. DeBattista C., Belanoff J., Glass S., Khan A., Horne R.L., Blasey C., Carpenter L.L., and Alva G. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol. Psychiatry 60 (2006) 1343-1349
21. De Kloet E.R., Vreugdenhil E., Oitzl M.S., and Joels M. Brain corticosteroid receptor balance in health and disease. Endocr. Rev. 19 (1998) 269-301
22. Dinan T.G. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br. J. Psychiatry 164 (1994) 365-371
23. Drago F., Nicolosi A., Micale V., and Lo Menzo G. Placebo affects the performance of rats in models of depression: is it a good control for behavioral experiments?. Eur. Neuropsychopharmacol. 11 (2001) 209-213
24. Duman R.S., and Monteggia L.M. A neurotorophic model for stress-related mood disorders. Biol. Psychiatry 59 (2006) 1116-1127
25. Espejo E.F., and Miñano F.J. Prefrontocortical dopamine depletion induces antidepressant-like effects in rats and alters the profile of desipramine during Porsolt's test. Neuroscience 88 (1999) 609-615
26. Faunt J.E., and Crocker A.D. Adrenocortical hormone status affects responses to dopamine receptor agonists. Eur. J. Pharmacol. 152 (1988) 255-261
27. Flores B.H., Kenna H., Keller J., Solvason H.B., and Schatzberg A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31 (2006) 628-636
28. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press, Inc., San Diego
29. Gregus A., Wintink A.J., Davis A.C., and Kalynchuk L.E. Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behav. Brain Res. 156 (2005) 105-114
30. Grippo A.J., Wu K.D., Hassan I., and Carter C.S. Social isolation in prairie voles induces behaviors relevant to negative affect: toward the development of a rodent model focused on co-occurring depression and anxiety. Depress. Anxiety 25 (2008) E17-E26
31. Hall F.S., Wilkinson L.S., Humby T., and Robbins T.W. Maternal deprivation of neonatal rats produces enduring changes in dopamine function. Synapse 32 (1999) 37-43
32. Henn F.A., and Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon?. Biol. Psychiatry 56 (2004) 146-150
33. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 (2000) 477-501
34. Horger B.A., and Roth R.H. The role of mesoprefrontal dopamine neurons in stress. Crit. Rev. Neurobiol. 10 (1996) 395-418
35. Jacobs B.L., Praag H., and Gage F.H. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol. Psychiatry 5 (2000) 262-269
36. Johnson S.A., Fournier N.M., and Kalynchuk L.E. Effect of different doses of corticosterone on depression-like behavior and HPA axis responses to a novel stressor. Behav. Brain Res. 168 (2006) 280-288
37. Kalynchuk L.E., Gregus A., Boudreau D., and Perrot-Sinal T.S. Corticosterone increases depression-like behavior, with some effects on predator odor-induced defensive behavior, in male and female rats. Behav. Neurosci. 118 (2004) 1365-1377
38. Karolewicz B., and Paul I.A. Group housing of mice increases immobility and antidepressant sensitivity in the forced swim and tail suspension tests. Eur. J. Pharmacol. 415 (2001) 197-201
39. Kawasaki T., Ishihara K., Ago Y., Baba A., and Matsuda T. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. J. Pharmacol. Exp. Ther. 322 (2007) 274-281
40. Koda K., Ago Y., Kawasaki T., Hashimoto H., Baba A., and Matsuda T. Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology 196 (2008) 293-301
41. Korte S.M., De Kloet E.R., Buwalda B., Bouman S.D., and Bohus B. Antisense of the glucocorticoid receptor in hippocampal dentate gyrus reduces immobility in forced swim test. Eur. J. Pharmacol. 301 (1996) 19-25
42. Kunugi H., Ida I., Owashi T., Kimura M., Inoue Y., Nakagawa S., Yabana T., Urushibara T., Kanai R., Aihara M., Yuuki N., Otsubo T., Oshima A., Kudo K., Inoue T., Kitaichi Y., Shirakawa O., Isogawa K., Nagayama H., Kamijima K., Nanko S., Kanba S., Higuchi T., and Mikuni M. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology 31 (2006) 212-220
43. Ladd C.O., Thrivikraman K.V., Huot R.L., and Plotsky P.M. Differential neuroendocrine responses to chronic variable stress in adult Long Evans rats exposed to handling-maternal separation as neonates. Psychoneuroendocrinology 30 (2005) 520-533
44. Lindley S.E., Bengoechea T.G., Schatzberg A.F., and Wong D.L. Glucocorticoid effects on mesotelencephalic dopamine neurotransmission. Neuropsychopharmacology 21 (1999) 399-407
45. Lindley S.E., Bengoechea T.G., Wong D.L., and Schatzberg A.F. Mesotelencephalic dopamine neurochemical responses to glucocorticoid administration and adrenalectomy in Fischer 344 and Lewis rats. Brain Res. 958 (2002) 414-422
46. Mayer J.L., Klumpers L., Maslam S., de Kloet E.R., Joëls M., and Lucassen P.J. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalizes the corticosterone-induced reduction of adult hippocampal neurogenesis. J. Neuroendocrinol. 18 (2006) 629-631
47. Micale V., Tamburella A., Leggio G.M., Mazzola C., Li Volsi V., and Drago F. Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol. Biochem. Behav. 90 (2008) 463-469
48. Morgan B.P., Swick A.G., Hargrove D.M., LaFlamme J.A., Moynihan M.S., Carroll R.S., Martin K.A., Lee E., Decosta D., and Bordner J. Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J. Med. Chem. 45 (2002) 2417-2424
49. Morrow B.A., Elsworth J.D., Rasmusson A.M., and Roth R.H. The role of mesoprefrontal dopamine neurons in the acquisition and expression of conditioned-fear in the rat. Neuroscience 92 (1999) 553-564
50. Murphy B.L., Arnsten A.F., Goldman-Rakic P.S., and Roth R.H. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc. Natl. Acad. Sci. U.S.A. 63 (1996) 1325-1329
51. Nestler E.J., Barrot M., Dileone R.J., Eisch A.J., Gold S.J., and Monteggia L.M. Neurobiology of depression. Neuron 34 (2002) 13-25
52. Oomen C.A., Mayer J.L., de Kloet E.R., Joëls M., and Lucassen P.J. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalizes the reduction in neurogenesis after chronic stress. Eur. J. Neurosci. 26 (2007) 3395-3401
53. Pani L., Porcella A., and Gessa G.L. The role of stress in the pathophysiology of the dopaminergic system. Mol. Psychiatry 5 (2000) 14-21
54. Peiffer A., Veilleux S., and Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 16 (1991) 505-515
55. Pepin M.C., Govindan M.V., and Barden N. Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol. Pharmacol. 41 (1992) 1016-1022
56. Pryce C.R., Ruedi Bettschen D., Dettling A.C., Weston A., Russig H., Ferger B., and Feldon J. Long-term effects of early-life environmental manipulations in rodents and primates: potential animal models in depression research. Neurosci. Biobehav. Rev. 29 (2005) 649-674
57. Przegalinski E., Budziszewska B., Siwanowicz J., and Jaworska L. The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats. Neuropharmacology 32 (1993) 1397-1400
58. Reus V.I., and Miner C. Evidence for physiological effects of hypercortisolemia in psychiatric patients. Psychiatry Res. 14 (1985) 47-56
59. Ridder S., Chourbaji S., Hellweg R., Urani A., Zacher C., Schmid W., Zink M., Hortnagl H., Flor H., Henn F.A., Schutz G., and Gass P. Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. J. Neurosci. 25 (2005) 6243-6250
60. Robbins T.W., Jones G.H., and Wilkinson L.S. Behavioural and neurochemical effects of early social deprivation in the rat. J. Psychopharmacol. 10 (1996) 39-47
61. Rougé-Pont F., Marinelli M., Le Moasl M., Simon H., and Piazza P.V. Stress-induced sensitization and glucocorticoids. II. Sensitization of the increase in extracellular dopamine induced by cocaine depends on stress-induced corticosterone secretion. J. Neurosci. 15 (1995) 7189-7195
62. 1A receptor activation in isolated mice. Eur. J. Pharmacol. 432 (2001) 163-166
63. 2A receptors of aggressive behavior in isolated mice. Jpn. J. Pharmacol. 89 (2002) 89-92
64. 1A receptor agonist MKC-242 reverse isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology 170 (2003) 73-79
65. Schatzberg A.F., and Lindley S. Glucocorticoid antagonists in neuropsychotic disorders. Eur. J. Pharmacol. 583 (2008) 358-364
66. Shatnawi A., Tran T., and Ratnam M. R5020 and RU486 act as progesterone receptor agonists to enhance Sp1/Sp4-dependent gene transcription by an indirect mechanism. Mol. Endocrinol. 21 (2007) 635-650
67. Spiga F., Harrison L.R., Wood S.A., Atkinson H.C., MacSweeney C.P., Thomson F., Craighead M., Grassie M., and Lightman S.L. Effect of the glucocorticoid receptor antagonist Org 34850 on basal and stress-induced corticosterone secretion. J. Neuroendocrinol. 19 (2007) 891-900
68. Tanda G., Carboni E., Frau R., and Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?. Psychopharmacology 115 (1994) 285-288
69. Tanda G., Bassareo V., and Di Chiara G. Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat. Psychopharmacology 123 (1996) 127-130
70. Van den Hove D.L., Blanco C.E., Aendekerk B., Desbonnet L., Bruschettini M., Steinbusch H.P., Prickaerts J., and Steinbusch H.W. Prenatal restraint stress and long-term affective consequences. Dev. Neurosci. 27 (2005) 313-320
71. Videbech P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. Acta Psychiatr. Scand. 101 (2000) 11-20
72. Webster N.J., Green S., Jin J.R., and Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54 (1988) 199-207
73. Zhao Y., Ma R., Shen J., Su H., Xing D., and Du L. A mouse model of depression induced by repeated corticosterone injections. Eur. J. Pharmacol. 581 (2008) 113-120